Post-Transplant Cyclophosphamide as a Potent Strategy for Bronchiolitis Obliterans Syndrome Prevention: A Comprehensive Clinical Synthesis
Posted inClinical Updates news Respiratory Transplantation

Post-Transplant Cyclophosphamide as a Potent Strategy for Bronchiolitis Obliterans Syndrome Prevention: A Comprehensive Clinical Synthesis

This review evaluates the role of post-transplant cyclophosphamide (PTCy) in reducing the risk of bronchiolitis obliterans syndrome (BOS), highlighting recent multicenter data that demonstrates a 75% risk reduction mediated by the prevention of chronic graft-versus-host disease.
Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients
Posted innews Oncology Respiratory

Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients

The NEOSAS-GFPC study demonstrates that severe sleep-related hypoxemia is an independent predictor of increased mortality in NSCLC patients, highlighting the clinical importance of monitoring nocturnal oxygen saturation beyond traditional apnea indices to improve prognostic accuracy and patient care.
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
Posted inAllergy & Immunology Clinical Updates news Respiratory

Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care

This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocating for a holistic approach to complex patient management.
Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial
Posted inAllergy & Immunology news Respiratory

Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial

The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammatory biomarkers.
Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
Posted inAllergy & Immunology news Respiratory

Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids

The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new evidence base for anti-inflammatory reliever strategies in moderate asthma.